{"pk":65130,"title":"Evaluation of Irinotecan as a Third- or Fourth-line Treatment for Advanced Non-small Cell Lung Cancer","subtitle":null,"abstract":"Lung cancer is the leading cause of cancer-related deaths in the United States. There are two major types of lung cancer: non-small cell lung cancer (NSCLC), which comprises approximately 85% of all lung cancers, and small cell lung cancer. Currently, the most prevalent third- and fourth- line treatment for non-small cell lung cancer is cisplatin-based therapy. This form of therapy has been long established as the chief treatment for advanced NSCLC; however, cisplatin-based therapy also impairs the replication of beneficial cells. Furthermore, insufficient research has been conducted regarding alternative third- and fourth-line treatments. We plan to test the efficacy of irinotecan, a drug that inhibits nuclear enzymes associated with DNA replication and transcription, as a third- or fourth-line treatment for advanced NSCLC in a phase III study. Irinotecan could provide NSCLC patients with an alternative treatment with lower risk of excessive toxicity. Furthermore, this study would supply the foundation for future research concerning later-line treatments for advanced NSCLC.","language":"en","license":null,"keywords":[{"word":"Evaluation"},{"word":"Irinotecan"},{"word":"treatment"},{"word":"advanced"},{"word":"non-small cell lung cancer"}],"section":"Articles","is_remote":true,"remote_url":"https://escholarship.org/uc/item/0nh7m2pg","frozenauthors":[{"first_name":"James","middle_name":"","last_name":"Keener","name_suffix":"","institution":"","department":""}],"date_submitted":"2013-12-20T09:29:39+01:00","date_accepted":"2013-12-20T09:29:39+01:00","date_published":"2013-12-20T09:00:00+01:00","render_galley":null,"galleys":[{"label":"","type":"pdf","path":"https://journalpub.escholarship.org/ucm_mwp_ucmurj/article/65130/galley/49898/download/"}]}